

## 2020 International Chordoma Research Workshop

All times are listed in ET

Thursday, July 16		
10:00 AM	Welcome	
	Josh Sommer, Chordoma Foundation	
10:10 AM - 12:05 PM	Session I: Current frontiers in clinical management	
	Moderator: Daniel Sciubba, Johns Hopkins Medical Institute	
	Surgical management of chordoma of the spine	
	Matthew Goodwin, Washington University	
	Surgical management of skull base chordoma	
	Sebastien Froelich, Université Paris Diderot	
	Definitive high-dose, proton-based radiation for unresected mobile spine and sacral chordomas	
	Tom DeLaney, Massachusetts General Hospital	
	Advances in hypofractionated radiation  Josh Yamada, Memorial Sloan Kettering Cancer Center	
	Josh Famada, Memorial Sloan Rettering Canter Center	
	Laser interstitial thermotherapy for management of metastatic spinal chordoma	
	Claudio Tatsui, The University of Texas MD Anderson Cancer Center	
	Clinical genomic sequencing to identify systemic therapies	
	Mrinal Gounder, Memorial Sloan Kettering Cancer Center	
	Q&A/Discussion	
12:10 - 1:10 PM	Session II: Collaborating to accelerate improvement in care Moderator: Greg Cote, Massachusetts General Hospital	
	SACRO study: An update	
	Stefano Radaelli, Fondazione IRCCS Istituto Nazionale dei Tumori	
	Looking back to move forward: A multi-institutional retrospective radiotherapy	
	study	
	Vinai Gondi, Northwestern Medicine	
	NCI natural history studies of rare solid tumors	
	Brigitte Widemann, National Cancer Institute	
	Mary Frances Wedekind Malone, National Cancer Institute	
	Q&A/Discussion	

1:10 - 1:25 PM	Break
1:25 - 3:00 PM	Session III: Lessons from recent clinical trials
	Moderator: Chris Heery, Precision BioSciences
	Afatinib in locally advanced and metastatic chordoma
	Astrid Lipplaa, Leiden University Medical Center
	Nivolumab with or without stereotactic radiosurgery in patients with recurrent, advanced, or metastatic chordoma
	Michael Lim, Johns Hopkins University Sidney Kimmel Cancer Center
	Pemetrexed: A pilot study
	Santosh Kesari, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence St. John's Health Center
	Results with volumetric analysis from a phase 2 clinical trial of a yeast-brachyury vaccine (GI-6301) with definitive radiation therapy in locally advanced, unresectable chordoma
	Peter DeMaria, National Cancer Institute
	Discussion on lessons learned

## **SPECIAL PEDIATRIC BREAKOUT SESSION**

3:30 - 5:00 PM ET NCI MyPART / Chordoma Foundation

Friday, July 17		
10:00 - 10:10 AM	Welcome	
	Joan Levy, Chordoma Foundation	
10:10 - 11:45 AM	Session I: Genomics and epigenomics	
	Moderator: Charles Lin, Kronos Bio	
	Centralizing datasets for the research community	
	Adam Resnick, Children's Hospital of Philadelphia	
	The identification of epigenomic predictors of chordoma development and recurrence	
	Jeffrey Zuccato, University of Toronto, University Health Network	
	Linking epigenetic landscape and clinical outcomes in patients with clival chordoma	
	Andrew Venteicher, University of Minnesota	
	Targeting SMARCB1 in chordoma development	
	Tara Walhart, University of North Carolina Chapel Hill	
	Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival Rose Yang, National Cancer Institute	
	Q&A/Discussion	
11:50 AM - 1:00 PM	Session II: Drugging brachyury Moderator: Rebecca Bish, The Mark Foundation for Cancer Research	
	Pharmacologic transcriptional CDK inhibition functions through targeting	
	brachyury autoregulation in chordoma Hadley Sheppard, Institute of Cancer Research, London	
	riadiey Sneppard, institute of Canter Nesearch, London	
	Using structural biology to aid development of small molecules targeting	
	Joseph Newman, University of Oxford	
	Joseph Newman, University of Oxford	
	Direct targeting of the transcription factor brachyury: Open science drug	
	discovery David Drewry, University of North Carolina Eshelman School of Pharmacy	
	Q&A/Discussion	
1:00 - 1:15 PM	Break	

1:15 - 2:15 PM	Session III: Immune biology and immunotherapy Moderator: Jim Hodge, National Cancer Institute
	Characterization of the cell surface proteome of chordoma cell lines:
	Identification of novel therapeutic targets
	Shahbaz Khan, Princess Margaret Cancer Center, University Health Network
	Exploring the unique epigenomic landscape of poorly differentiated chordoma Stephen Yip, Vancouver General Hospital
	CRI/CF Clinic and Laboratory Integration Program award Jill O'Donnell Tormey, Cancer Research Institute
	Identification of TCR targets for chordoma
	Cassian Yee, MD Anderson Cancer Center
	Q&A/Discussion
2:20 - 3:55 PM	Session IV: New and emerging targets and drugs
	Moderator: Mike Kelley, Duke University School of Medicine
	The XPO1 inhibitor Selinexor demonstrates potent anti-cancer activity in PDX
	mouse models of chordoma
	Christopher Walker, Karyopharm Therapeutics
	Identifying candidate systemic therapies for chordoma via CRISPR-Cas9 and drug repurposing screens
	Tanaz Sharifnia, Broad Institute of Harvard and MIT
	Synergistic drug combinations and machine learning for drug repurposing in chordoma and Chordoma drug target discovery using the kinase chemogenomic set (KCGS)
	Edward Anderson, University of North Carolina Eshelman School of Pharmacy
	Targeting physaliferous vacuoles to induce chordoma cell self-destruct mechanisms - a new direction for developing chordoma therapeutics Stuart Fraser, University of Sydney
	CF Drug Screening Program: Current uses and future directions Joan Levy, Chordoma Foundation
	Q&A/Discussion
3:55 - 4:00 PM	Concluding remarks Josh Sommer, Chordoma Foundation

## **VIRTUAL POSTER SESSION**

Beginning on July 16
For viewing by 2020 ICRW participants only